Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
NCT01449461 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
- Lead sponsor
- Ariad Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 20, 2011
- Completion date
- February 18, 2020
- Enrollment
- 137 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.